Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway.

Laprevotte E, Cochaud S, du Manoir S, Lapierre M, Dejou C, Philippe M, Giustiniani J, Frewer KA, Sanders AJ, Jiang WG, Michaud HA, Colombo PE, Bensussan A, Alberici G, Bastid J, Eliaou JF, Bonnefoy N.

Oncotarget. 2017 Dec 6;8(69):113360-113372. doi: 10.18632/oncotarget.23008. eCollection 2017 Dec 26.

2.

Trem-1 is not crucial in psoriasiform imiquimod-induced skin inflammation in mice.

Joffre J, Hau E, Zeboudj L, Laurans L, Battistella M, Boufenzer A, Masson A, Le Buanec H, Cochaud S, Bagot M, Bensussan A, Gibot S, Bouaziz JD, Ait-Oufella H.

Exp Dermatol. 2016 May;25(5):400-2. doi: 10.1111/exd.12944. No abstract available.

PMID:
26782119
3.

IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells.

Mombelli S, Cochaud S, Merrouche Y, Garbar C, Antonicelli F, Laprevotte E, Alberici G, Bonnefoy N, Eliaou JF, Bastid J, Bensussan A, Giustiniani J.

Sci Rep. 2015 Jul 8;5:11874. doi: 10.1038/srep11874.

4.

Neuropeptides of the VIP family inhibit glioblastoma cell invasion.

Cochaud S, Meunier AC, Monvoisin A, Bensalma S, Muller JM, Chadéneau C.

J Neurooncol. 2015 Mar;122(1):63-73. doi: 10.1007/s11060-014-1697-6. Epub 2015 Jan 7.

PMID:
25563813
5.

Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.

Bastid J, Regairaz A, Bonnefoy N, Déjou C, Giustiniani J, Laheurte C, Cochaud S, Laprevotte E, Funck-Brentano E, Hemon P, Gros L, Bec N, Larroque C, Alberici G, Bensussan A, Eliaou JF.

Cancer Immunol Res. 2015 Mar;3(3):254-65. doi: 10.1158/2326-6066.CIR-14-0018. Epub 2014 Nov 17.

6.

IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2.

Cochaud S, Giustiniani J, Thomas C, Laprevotte E, Garbar C, Savoye AM, Curé H, Mascaux C, Alberici G, Bonnefoy N, Eliaou JF, Bensussan A, Bastid J.

Sci Rep. 2013 Dec 9;3:3456. doi: 10.1038/srep03456.

7.

Neuropeptide Y inhibits interleukin-1 beta-induced microglia motility.

Ferreira R, Santos T, Cortes L, Cochaud S, Agasse F, Silva AP, Xapelli S, Malva JO.

J Neurochem. 2012 Jan;120(1):93-105. doi: 10.1111/j.1471-4159.2011.07541.x. Epub 2011 Nov 17.

8.

The vasoactive intestinal peptide-receptor system is involved in human glioblastoma cell migration.

Cochaud S, Chevrier L, Meunier AC, Brillet T, Chadéneau C, Muller JM.

Neuropeptides. 2010 Oct;44(5):373-83. doi: 10.1016/j.npep.2010.06.003. Epub 2010 Jul 17.

PMID:
20638719
9.

Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line.

Chevrier L, Meunier AC, Cochaud S, Muller JM, Chadéneau C.

Int J Oncol. 2008 Nov;33(5):1081-9.

PMID:
18949372

Supplemental Content

Loading ...
Support Center